Compare SNT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNT | KPTI |
|---|---|---|
| Founded | 1965 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9M | 36.7M |
| IPO Year | 2023 | 2013 |
| Metric | SNT | KPTI |
|---|---|---|
| Price | $1.43 | $0.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 13.9K | ★ 1.2M |
| Earning Date | 11-24-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $27.98 |
| P/E Ratio | $19.22 | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $1.42 | $0.40 |
| 52 Week High | $5.34 | $10.99 |
| Indicator | SNT | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 31.12 | 13.36 |
| Support Level | N/A | N/A |
| Resistance Level | $1.67 | $2.16 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 0.00 | 0.00 |
Senstar Technologies Corp is an international provider of comprehensive physical, video, and access control security products and solutions. The company offers comprehensive solutions for critical sites, which leverage its broad portfolio of homegrown PIDS (Perimeter Intrusion Detection Systems), advanced VMS and SMS (Video Management Software and Security Management Software) with native IVA (Intelligent Video Analytics) security solutions, as well as access control products and technologies. Geographically, the company operates in North America, which derives maximum revenue; Europe; APAC; South and Latin America; and Others.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).